Share-based Payment Arrangement, Expense of AXIM BIOTECHNOLOGIES, INC. from 31 Dec 2019 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AXIM BIOTECHNOLOGIES, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Jun 2024.
  • AXIM BIOTECHNOLOGIES, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2024 was $9,613, a 50% decline year-over-year.
  • AXIM BIOTECHNOLOGIES, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2024 was $93,905, a 89% decline year-over-year.
  • AXIM BIOTECHNOLOGIES, INC. annual Share-based Payment Arrangement, Expense for 2023 was $197,727, a 82% decline from 2022.
  • AXIM BIOTECHNOLOGIES, INC. annual Share-based Payment Arrangement, Expense for 2022 was $1,107,494, a 3.2% decline from 2021.
  • AXIM BIOTECHNOLOGIES, INC. annual Share-based Payment Arrangement, Expense for 2021 was $1,143,730, a 41% decline from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

AXIM BIOTECHNOLOGIES, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $93,905 $9,613 -$9,613 -50% 01 Apr 2024 30 Jun 2024 10-Q 19 Aug 2024 2024 Q2
Q1 2024 $103,518 $9,613 -$94,209 -91% 01 Jan 2024 31 Mar 2024 10-Q/A 22 May 2024 2024 Q1
Q4 2023 $197,727 $36,264 -$182,918 -83% 01 Oct 2023 31 Dec 2023 10-K 16 Apr 2024 2023 FY
Q3 2023 $380,645 $38,415 -$478,765 -93% 01 Jul 2023 30 Sep 2023 10-Q 20 Nov 2023 2023 Q3
Q2 2023 $859,410 $19,226 -$162,989 -89% 01 Apr 2023 30 Jun 2023 10-Q 19 Aug 2024 2024 Q2
Q1 2023 $1,022,399 $103,822 -$85,095 -45% 01 Jan 2023 31 Mar 2023 10-Q/A 22 May 2024 2024 Q1
Q4 2022 $1,107,494 $219,182 +$308,136 01 Oct 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
Q3 2022 $799,358 $517,180 -$244,630 -32% 01 Jul 2022 30 Sep 2022 10-Q 20 Nov 2023 2023 Q3
Q2 2022 $1,043,988 $182,215 -$188,917 -51% 01 Apr 2022 30 Jun 2022 10-Q 21 Aug 2023 2023 Q2
Q1 2022 $1,232,905 $188,917 +$89,175 +89% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023 2023 Q1
Q4 2021 $1,143,730 $88,954 01 Oct 2021 31 Dec 2021 10-K 17 Apr 2023 2022 FY
Q3 2021 $761,810 +$346,971 +84% 01 Jul 2021 30 Sep 2021 10-Q/A 15 Nov 2022 2022 Q3
Q2 2021 $371,132 +$371,132 01 Apr 2021 30 Jun 2021 10-Q 16 Aug 2022 2022 Q2
Q1 2021 $99,742 01 Jan 2021 31 Mar 2021 10-Q 16 Aug 2022 2022 Q2
Q3 2020 $414,839 01 Jul 2020 30 Sep 2020 10-Q 22 Nov 2021 2021 Q3
Q2 2020 $0 01 Apr 2020 30 Jun 2020 10-Q 23 Aug 2021 2021 Q2

AXIM BIOTECHNOLOGIES, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $197,727 -$909,767 -82% 01 Jan 2023 31 Dec 2023 10-K 16 Apr 2024 2023 FY
2022 $1,107,494 -$36,236 -3.2% 01 Jan 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
2021 $1,143,730 -$804,015 -41% 01 Jan 2021 31 Dec 2021 10-K 17 Apr 2023 2022 FY
2020 $1,947,745 +$127,745 +7% 01 Jan 2020 31 Dec 2020 10-K/A 26 Apr 2021 2020 FY
2019 $1,820,000 01 Jan 2019 31 Dec 2019 10-K/A 26 Apr 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.